fashion -WSS

fashion

author：focus 2025-10-01 17:21:45 - browse：13

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Medicare to cover more brain scans for Alzheimer’s patients

hotspot

WSS

At Orexo, a ‘turning point’ for everything but digital health

'A game

As digital health tech proliferates, a new institute aims to cut through hype

Group opposing PBM reform sets lobbying record

David Liu startup to focus on CRISPR delivery

How dance can help nurses traumatized by Covid

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Cancer drug shortages should be causing more outrage

Group opposing PBM reform sets lobbying record

In Memoriam: Notable people who died in 2023

People with substance use disorder deserve online privacy

Peter Hotez and the public health issue of online harassment

Biden tests positive for Covid

Bright Health sells Medicare Advantage business to Molina

STAT Virtual Event: The State of Biosimilars: What to Watch

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Wikipedia

House panel takes first step toward fixing drug shortages

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

PBMs drew scrutiny in House hearing — and so did pharma

Senate bill would ban some hospital facility fees

Free Covid tests will again be offered to all U.S. households

As digital health tech proliferates, a new institute aims to cut through hype

leisure time

hotspot

hotspot

hotspot